These stocks are both experts in their respective fields.Many billionaire investors are going all in on artificial intelligence (AI). That's understandable. AI is quickly being integrated into businesses' day-to-day operations. The leaders in the field could deliver outsized returns. However, there are other exciting investment opportunities out there. Consider Renaissance Technologies, a hedge fund headed by Jim Simons. The fund's holdings feature several healthcare stocks. That includes two notable drugma ...

Have you assessed how the international operations of Exelixis (EXEL) performed in the quarter ended March 2024? For this drug developer, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.In the modern, closely-knit global economic landscape, the capacity of a business to access foreign markets is often a key determinant of its financial well-being and growth path. Investors now place great importan ...

Exelixis, Inc. (EXEL) reported lower-than-expected results for the first quarter. Its shares fell 7% in after-hours trading following the announcement.EXEL recorded earnings of 17 cents per share, which missed the Zacks Consensus Estimate of 28 cents. The company registered adjusted earnings of 16 cents per share in the first quarter of 2023.Including stock-based compensation expense, EPS was 12 cents, flat year over year.Net revenues were $425.2 million, which lagged the Zacks Consensus Estimate of $468 mi ...

For the quarter ended March 2024, Exelixis (EXEL) reported revenue of $425.23 million, up 4% over the same period last year. EPS came in at $0.17, compared to $0.16 in the year-ago quarter.The reported revenue represents a surprise of -9.07% over the Zacks Consensus Estimate of $467.64 million. With the consensus EPS estimate being $0.28, the EPS surprise was -39.29%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their n ...

Financial Performance - Total revenues for Q1 2024 were $425.2 million, up from $408.8 million in Q1 2023, representing a 3.4% increase[3] - U.S. net product revenues from the cabozantinib franchise were $378.5 million, compared to $363.4 million in Q1 2023, reflecting a 4.1% increase[4] - Collaboration revenues increased to $46.7 million in Q1 2024 from $45.4 million in Q1 2023, primarily due to higher royalty revenues[5] - Exelixis reported net product revenues of $378.5 million for Q1 2024, an increase of 4.3% compared to $363.4 million in Q1 2023[30] - Total revenues for Q1 2024 were $425.2 million, up 4.0% from $408.8 million in Q1 2023[30] - The company incurred total operating expenses of $395.8 million in Q1 2024, compared to $380.0 million in Q1 2023, reflecting a 4.0% increase[30] Expenses - Research and development expenses decreased to $227.7 million in Q1 2024 from $234.2 million in Q1 2023, a reduction of 2.1%[6] - Selling, general and administrative expenses fell to $114.0 million in Q1 2024 from $131.4 million in Q1 2023, a decrease of 13.3%[7] Net Income - GAAP net income for Q1 2024 was $37.3 million, or $0.12 per share, compared to $40.0 million, or $0.12 per share, in Q1 2023[9] - Exelixis' net income for Q1 2024 was $37.3 million, a decrease of 6.5% from $40.0 million in Q1 2023[30] - Non-GAAP net income for Q1 2024 was $52.0 million, or $0.17 per share, slightly down from $52.8 million, or $0.16 per share, in Q1 2023[10] Future Guidance and Plans - The company maintains its 2024 financial guidance, projecting total revenues between $1.825 billion and $1.925 billion[14] - Exelixis plans to file up to three Investigational New Drug applications in 2024, pending supportive preclinical data[2] - The company plans to submit Investigational New Drug filings for up to three development candidates in 2024, pending supportive preclinical data[27] - Exelixis anticipates advancing regulatory strategies for cabozantinib label expansions, which could drive future revenue growth[27] Shareholder Returns - As of March 31, 2024, Exelixis repurchased $190.7 million of its common stock, with an additional $450 million authorized for repurchase by the end of 2024[21] - The company expects to repurchase up to an additional $450 million of its common stock before the end of 2024, aiming to return $1 billion to shareholders over two years[27] Restructuring and Development - Exelixis' restructuring efforts are expected to enhance integrated research, development, and commercial capabilities[27]

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Regeneron (REGN) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with p ...

Exelixis Inc. (EXEL, Financial) is a pharmaceutical company headquartered in Alameda, California that focuses on developing medicines to treat patients with various types of cancer. Investment thesis In recent years, the company's management has continued to delight investors with significant growth in its commercial business and expansion of its drug development pipeline, making Exelixis a leading player in the renal cell carcinoma market. The first investment thesis we highlight is the detailed results of ...

Exelixis (EXEL) has been beaten down lately with too much selling pressure. While the stock has lost 10.9% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that ...

A downtrend has been apparent in Exelixis (EXEL) lately with too much selling pressure. The stock has declined 10% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting ...

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Regeneron (REGN) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank emphasizes companies w ...